Gene News and Research

Latest Gene News and Research

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients - those with estrogen receptor (ER)-positive/HER2-negative disease.

10 Dec 2010

Silencing the TLR4 gene can prevent cardiovascular disease in diabetic patients

Silencing the TLR4 gene can stop the process which may lead to cardiovascular disease in diabetic patients. Researchers demonstrated that TLR4 plays a critical role in hyperglycaemic cardiac apoptosis, and that silencing the gene using specific small interfering RNA can prevent it.

10 Dec 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Memgen, LLC announced the presentation of clinical and preclinical results for its lead product, ISF35, during the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The research and clinical development of ISF35 announced today was led by Januario Castro, MD, and Thomas Kipps, MD, PhD, both at the University of California, San Diego.

10 Dec 2010

VCP gene causes some instances of familial ALS: Researchers

Using a new gene sequencing method, a team of researchers led by scientists from Johns Hopkins and the National Institutes of Health has discovered a gene that appears to cause some instances of familial amyotrophic lateral sclerosis. The finding could lead to novel ways to treat the more common form of this fatal neurodegenerative disease, which kills the vast majority of the nearly 6,000 Americans diagnosed with ALS every year.

10 Dec 2010

Dogs help understand primary ciliary dyskinesia

A dog is mankind's best friend : the old saying has once again been borne out through a medical discovery concerning the genetic origins of primary ciliary dyskinesia (PCD). In using dogs as a research model in the framework of the European LUPA project, a team from the University of Liège's GIGA-Research Unit has been able to bring to light new mutations in a specific gene responsible for the development of the disease in human beings.

9 Dec 2010

Excreted antibiotics become potential sources of antibiotic resistant genes

When an antibiotic is consumed, researchers have learned that up to 90 percent passes through a body without metabolizing. This means the drugs can leave the body almost intact through normal bodily functions.

9 Dec 2010

Walter and Eliza Hall Institute researcher awarded 2011 Gani Medal for Human Genetics

Major advances in our understanding of human evolution have seen Walter and Eliza Hall Institute researcher Dr Alicia Oshlack awarded the 2011 Gani Medal for Human Genetics by the Australian Academy of Science.

9 Dec 2010

Cellectis bioresearch announces winner of The Genome Customization Award

Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), has today announced the recipient of its post-doctoral fellowship award program. The Genome Customization Award (TGCA) is going to Dr Nelson Lau's research group, from the Department of Biology at the Brandeis University (Waltham, Massachusetts).

9 Dec 2010

Research findings could lead to new therapies to correct neurological disorders

Yale University researchers have found that a single molecule not only connects brain cells but also changes how we learn. The findings, reported in the December 9 issue of the journal Neuron, may help researchers discover ways to improve memory and could lead to new therapies to correct neurological disorders.

9 Dec 2010

p53 activation offers a novel strategy for cancer therapy

A pioneering clinical trial is testing the effectiveness in leukemia of a small molecule that shuts down MDM2, a protein that can disable the well-known tumor suppressor p53.

9 Dec 2010

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Open Monoclonal Technology, Inc. (OMT) today announced its new human antibody platform using the first genetically engineered rats expressing a human antibody repertoire. The company, which also created the first targeted knockout rats in 2009, is now cross-breeding the knockout animals with the rats expressing human antibodies to finalize its platform.

9 Dec 2010

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Celgene International Sàrl today announced that its next IMiD compound, pomalidomide, was evaluated in three separate investigational trials of patients with multiple myeloma who were relapsed or refractory after prior treatments including lenalidomide, thalidomide and bortezomib. The clinical data were presented at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

9 Dec 2010

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

DPT Laboratories, Ltd., a pharmaceutical contract development and manufacturing organization, announced today that it received FDA approval to manufacture commercial supplies of a leading sterile ointment for wound care at its Center of Excellence for Sterile & Specialty Products in Lakewood, N.J. Beginning this month, Healthpoint will ship commercial lots of Collagenase SANTYL® Ointment produced at DPT's Lakewood facility to its North American customers.

9 Dec 2010

Genetics in Medicine: Women who carry high-risk BRCA mutations opt for surgery

In women who test positive for BRCA 1/2 mutations associated with a high risk of breast or ovarian cancer, some key psychological factors influence the decision to undergo risk-reducing surgery, reports the December Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.

8 Dec 2010

Medulloblastoma subtypes are separate diseases with different origins

International effort led by St. Jude Children's Research Hospital scientists is expected to fuel development of targeted therapies and aid the search for unique combinations of cells and mutations that lead to other cancers.

8 Dec 2010

ChipDX validates genetic signature for early-stage colon cancer

ChipDX LLC, a New York-based online molecular diagnostics and personalized medicine company, discovered and validated a genetic signature for early-stage colon cancer and is developing an online screening application to enable clinicians to more accurately identify risk of recurrence. In the study, published in the December issue of the British Journal of Cancer, ChipDX demonstrates how the 163-gene signature stratifies colon cancer patients into high- and low-risk groups for recurrence with greater accuracy than current methods.

8 Dec 2010

Bioengineers explain why some neurons die sooner than others in brains of AD patients

Bioengineers from the University of California, San Diego developed an explanation for why some types of neurons die sooner than others in the brains of people with Alzheimer's disease. These insights, published in the journal Nature Biotechnology on November 21, come from detailed models of brain energy metabolism developed in the Department of Bioengineering at the UC San Diego Jacobs School of Engineering.

8 Dec 2010

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

Case Western Reserve University School of Medicine faculty members are reaping the rewards of funding from the National Institutes of Health, in the form of grants and contracts. The funding totals more than $6.4 million for four different research endeavors.

8 Dec 2010

New technique may help develop novel treatments for brain diseases

Scientists have created a way to isolate neural stem cells - cells that give rise to all the cell types of the brain - from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson's and Huntington's diseases and spinal cord injury.

8 Dec 2010

QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis

QLT Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for QLT091001, its oral synthetic retinoid, for the treatment of Leber Congenital Amaurosis (LCA). LCA is an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.

8 Dec 2010

Gene News and Research

Latest Gene News and Research

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Silencing the TLR4 gene can prevent cardiovascular disease in diabetic patients

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

VCP gene causes some instances of familial ALS: Researchers

Dogs help understand primary ciliary dyskinesia

Excreted antibiotics become potential sources of antibiotic resistant genes

Walter and Eliza Hall Institute researcher awarded 2011 Gani Medal for Human Genetics

Cellectis bioresearch announces winner of The Genome Customization Award

Research findings could lead to new therapies to correct neurological disorders

p53 activation offers a novel strategy for cancer therapy

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

Genetics in Medicine: Women who carry high-risk BRCA mutations opt for surgery

Medulloblastoma subtypes are separate diseases with different origins

ChipDX validates genetic signature for early-stage colon cancer

Bioengineers explain why some neurons die sooner than others in brains of AD patients

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

New technique may help develop novel treatments for brain diseases

QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer